Selected article for: "binding domain and RBD domain"
Author: Munitz, A.; Edry-Botzer, L.; Itan, M.; Tur-Kaspa, R.; Dicker, D.; Markovitch, D.; Goren, M.; Mor, M.; Lev, S.; Gottesman, T.; Muhsen, K.; Cohen, D.; Qimron, U.; Freund, N.; Wine, Y.; Gerlic, M.; Stein, M.
Title: SARS-CoV-2 serological testing using electrochemiluminescence reveals arapid onset of seroconversion in severe COVID-19 patients
  • Cord-id: 8qplxnoh
  • Document date: 2020_6_30
    • ID: 8qplxnoh
    Snippet: Despite ongoing efforts to characterize the host response toward SARS-CoV-2, a major gap in our knowledge still exists regarding the magnitude and duration of the humoral response. We report the development of a rapid, highly specific and sensitive electrochemiluminescent assay for detecting IgM, IgA, and IgG antibodies toward two distinct SARS-CoV-2 antigens namely, the receptor binding domain (RBD) and the nuclear protein (NP). Whereas IgM antibodies toward RBD were detected at early stages of
    Document: Despite ongoing efforts to characterize the host response toward SARS-CoV-2, a major gap in our knowledge still exists regarding the magnitude and duration of the humoral response. We report the development of a rapid, highly specific and sensitive electrochemiluminescent assay for detecting IgM, IgA, and IgG antibodies toward two distinct SARS-CoV-2 antigens namely, the receptor binding domain (RBD) and the nuclear protein (NP). Whereas IgM antibodies toward RBD were detected at early stages of the disease, IgM antibodies against NP did not develop. Analysis of the antibody response in mild versus moderate/severe patients revealed a rapid onset of IgG and IgA antibodies, specifically in moderate/severe patients. Finally, we observed a marked reduction in IgM/IgA antibodies and to lesser extent, IgG, over time. We provide a comprehensive analysis of the human antibody response, and has major implications on our understanding and monitoring of SARS-CoV-2 infections, as well as finding effective vaccines.

    Search related documents:
    Co phrase search for related documents
    • accurate rapid and acute phase: 1, 2
    • accurate rapid and additional advantage: 1
    • accurate rapid and low serum dilution: 1
    • active disease and acute phase: 1, 2, 3, 4, 5
    • active disease and adaptive immunity: 1, 2, 3, 4
    • active disease and additional life: 1
    • active disease and lymphocyte crp: 1
    • acute phase and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute phase and additional antigen: 1
    • acute phase and additional life: 1, 2
    • acute phase and long term damage: 1, 2, 3, 4, 5, 6
    • acute phase and low serum dilution: 1
    • acute phase and lymphocyte crp: 1, 2, 3, 4, 5, 6, 7
    • adaptive immunity and long last immunity: 1
    • adaptive immunity and long term damage: 1